Vemurafenib
Authors:
- Keith. T FlahertyKFKeith. T Flaherty
- Uma YasothanUYUma Yasothan
- Peter KirkpatrickPKPeter Kirkpatrick
- 31 October 2011
- journal article
- Published by Springer Nature in Nature Reviews Drug Discovery
- Vol. 10 (11) , 811-812
Abstract
In August 2011 vemurafenib (Zelboraf; Daiichi Sankyo/Roche), an inhibitor of BRAF kinase, was approved by the US Food and Drug Administration (FDA) for the treatment of patients with unresectable or metastatic melanoma with the BRAF(V600E) mutation.Keywords
This publication has 8 references indexed in Scilit:
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationNew England Journal of Medicine, 2011
- Systematic Review of Medical Treatment in Melanoma: Current Status and Future ProspectsThe Oncologist, 2011
- Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanomaNature, 2010
- Inhibition of Mutated, Activated BRAF in Metastatic MelanomaNew England Journal of Medicine, 2010
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Selective BRAFV600E Inhibition Enhances T-Cell Recognition of Melanoma without Affecting Lymphocyte FunctionCancer Research, 2010
- Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activityProceedings of the National Academy of Sciences, 2008
- Mutations of the BRAF gene in human cancerNature, 2002